{
    "clinical_study": {
        "@rank": "143017", 
        "arm_group": [
            {
                "arm_group_label": "Octreotide", 
                "arm_group_type": "Experimental", 
                "description": "Octreotide 100mcg subcutaneous every 8 hours for 5 days"
            }, 
            {
                "arm_group_label": "no octreotide", 
                "arm_group_type": "No Intervention", 
                "description": "no octreotide"
            }
        ], 
        "brief_summary": {
            "textblock": "Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or\n      ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm."
        }, 
        "brief_title": "Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Adenoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenoma", 
                "Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Inclusion Criteria:\n\n      Duodenal or ampullary adenoma greater than or equal to 10mm. Duodenal or ampullary adenoma\n      that is suitable for endoscopic mucosal resection.\n\n      Medically fit for anesthesia, endoscopy, and EMR Able to provide Informed Consent 18 years\n      or older, male and female\n\n      Exclusion criteria:\n\n      Duodenal or ampullary adenoma <10mm Duodenal or ampullary adenoma that is not suitable for\n      endoscopic mucosal resection Medically unfit for anesthesia, endoscopy, or EMR Unable to\n      provide Informed Consent Less than 18 years old Allergy to Octreotide"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Duodenal or ampullary adenoma greater than or equal to 10mm Duodenal or ampullary adenoma\n        that is suitable for endoscopic mucosal resection Medically fit for anesthesia, endoscopy,\n        and EMR Able to provide Informed Consent 18 years or older, male and female\n\n        Exclusion Criteria:\n\n        Duodenal or ampullary adenoma <10mm Duodenal or ampullary adenoma that is not suitable for\n        endoscopic mucosal resection Medically unfit for anesthesia, endoscopy, or EMR Unable to\n        provide informed consent Less than 18 years old Allergy to Octreotide"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "89 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032784", 
            "org_study_id": "541923"
        }, 
        "intervention": {
            "arm_group_label": "Octreotide", 
            "description": "Octreotide 100mg subcutaneous every 8 hours for 5 days", 
            "intervention_name": "octreotide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Octreotide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "contact": {
                "email": "amy.logue@flhosp.org", 
                "last_name": "Amy L Logue, MSN", 
                "phone": "407-303-9736"
            }, 
            "contact_backup": {
                "email": "robert.hawes.MD@flhosp.org", 
                "last_name": "Robert Hawes, MD", 
                "phone": "407-303-2570"
            }, 
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32803"
                }, 
                "name": "Florida Hospital"
            }, 
            "investigator": {
                "last_name": "Robert Hawes, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding", 
        "overall_contact": {
            "email": "amy.logue@flhosp.org", 
            "last_name": "Amy L Logue, MSN", 
            "phone": "407-303-9736"
        }, 
        "overall_contact_backup": {
            "email": "robert.hawes.md@flhosp.org", 
            "last_name": "Robert Hawes, MD", 
            "phone": "407-303-2570"
        }, 
        "overall_official": {
            "affiliation": "Florida Hospital", 
            "last_name": "Robert Hawes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "clinical evidence of a bleed, including melena, hematochezia, hematemesis", 
            "measure": "Post endoscopic mucosal resection bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "3 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032784"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Florida Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Florida Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}